Novo Nordisk: Credit Suisse downgrades stock

(CercleFinance.com) - Credit Suisse has downgraded its rating on the Novo Nordisk share from "outperform" to "neutral," maintaining its target price at 470 Danish kronor.


"Following a strong performance over 2020, we believe the risk/reward outlook is more balanced," the broker says.

Credit Suisse estime si le premier semestre devrait s'avérer " solide ", l'année 2021 est " peu susceptible d'être une année de transformation ". Le CA annuel devrait croître de 7 % estime le broker, soit une augmentation en ligne avec le consensus.

Credit Suisse believes that while the first half of the year should be "solid", 2021 is "unlikely to be a transformational year". In 2021 analysts estimate Novo will report +7% revenue growth, in line with the consensus.


Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.